New study [1].
"After a decline in PSA test usage, there has been an increased burden of late‐stage disease, and the decline in prostate cancer mortality has leveled off."
The following quotes are from the NIH [2].
"... incidence of distant disease—that is, of cancer that has spread from the original tumor to other parts of the body—increased from a low rate of 7.8 new cases per 100,000 in 2010 to 9.2 new cases per 100,000 in 2014."
"“The increase in late-stage disease and the flattening of the mortality trend occurred contemporaneously with the observed decrease in PSA screening in the population,” said Serban Negoita, M.D., Dr.P.H., of NCI’s Surveillance Research Program and lead author of the prostate cancer report. “Although suggestive, this observation does not demonstrate that one caused the other, as there are many factors that contribute to incidence and mortality, such as improvements in staging and treating cancer."
Note the context of the news about the flat PCa mortality rate: "cancer mortality continues to decline" - but not for PCa.
I was diagnosed in 2004. Looking at the mortality trend at that point, it was clear that there had been a steady drop in the PCa mortality rate beginning with the adoption of PSA screening. And yet we had no drug breakthroughs in this period. Men were being treated much the same & yet fewer were dying.
& now, when we have so many more options, we see no improvement in mortality at all:
"after two decades of decline between 1993 and 2013, prostate cancer mortality leveled off between 2013 and 2015"
An interesting finding is that the rates for Gleason score 9-10 have not increased with the reduction in screening. More are being found at a later stage. Any group survival advantage to use of Zytiga, Xtandi & the others seems to have been eroded by more men being treated later.
Full report: [3].
Washington Post: [4].
-Patrick
[1] onlinelibrary.wiley.com/doi...
[2] nih.gov/news-events/news-re...